Inside Peptides
Search
Menu

Semaglutide

What it is. What the evidence says.

A prescription medicine that imitates GLP-1, a gut hormone involved in blood-sugar control and appetite.

Strong EvidenceApproved Medicine

Predominant research setting. Clinical confidence is claim-specific.

Updated Scientific review pending
Start with the basics Regulatory status ↓
Sequence diagram and chemical structure information for Semaglutide.
Semaglutide Chemical Structure & Sequence · Inside Peptides Scientific Library
Compound
Semaglutide (Synthetic GLP-1 RA)
Human effectiveness
Established for specific product indications; not every proposed use
Regulatory status
FDA-Approved Medicine
START HERE · PLAIN LANGUAGE

Semaglutide: the basics

What is it?

A prescription medicine that imitates GLP-1, a gut hormone involved in blood-sugar control and appetite.

Research paper ↗

What do people claim it helps with?

Better blood-sugar control and weight management have clinical support in appropriate patients. Broader wellness and anti-aging claims need separate evidence.

What has research actually shown?

Large human trials found improved blood-sugar control and substantial average weight loss in defined patient groups. Outcomes differ between people and depend on the product, treatment and condition.

Research paper ↗

Has this been demonstrated in people?

Demonstrated in people, including controlled clinical trials for the uses described here. Evidence for one diagnosis does not establish benefit for every other claim.

Research paper ↗

What side effects, risks and unknowns should I understand?

Nausea, vomiting, diarrhea or constipation are common. Important concerns include pancreatitis, gallbladder problems and dehydration. Certain products carry a thyroid-tumor warning and are contraindicated with personal or family medullary thyroid cancer or MEN2, an inherited endocrine disorder. The thyroid warning is based on animal findings; the human risk is uncertain.

Prescribing information ↗

Is it an approved medicine?

Yes. FDA-approved products include Ozempic and Rybelsus for type 2 diabetes and Wegovy for weight management, with additional product-specific indications. A generic peptide listing is not an approved product.

Prescribing information ↗

Approval here means U.S. FDA approval and applies to a particular product, formulation and use. This is a starting overview, not a complete side-effect list. Sources checked 10 October 2026; independent scientific review pending.

How is it used or studied?

Prescription injection or tablet, depending on the product. The formulations and indications differ.

Different routes and formulations can have different effects. A study of one product does not validate every product with the same peptide name.

A common misunderstanding

Native GLP-1, semaglutide and other GLP-1 medicines are not interchangeable.

What should I ask a clinician?
  • What diagnosis or goal are we trying to address, and what established options are available?
  • Was the expected benefit shown in people like me, using this exact product?
  • How could my medicines, health conditions or pregnancy plans affect the risks?
  • What monitoring is needed, and what would tell us the treatment is helping or should be stopped?
What do the research words mean?
Peptide
A short chain of amino acids, the building blocks of proteins.
Preclinical
Research in cells, tissues or animals before dependable treatment evidence in people.
Controlled trial
A study comparing a treatment with another treatment or a placebo to help separate its effects from other explanations.
Biomarker
A measurement, such as a hormone level. A change does not necessarily mean someone feels better or lives longer.
THE AVAILABLE RESEARCH

Semaglutide Research: Mechanism, Trial Results and Limitations

Human Clinical Evidence

Established Clinical Trials

STEP 1 studied weight outcomes in adults without diabetes; SELECT studied cardiovascular events in people with established cardiovascular disease; FLOW studied kidney and cardiovascular outcomes in type 2 diabetes with chronic kidney disease. These are different questions, not interchangeable measures of effectiveness.

Preclinical & Pharmacological Data

Laboratory & In Vivo Assays

Receptor and laboratory studies help explain biological action. They do not replace clinical outcomes, and an appetite mechanism does not guarantee a particular amount of weight loss for an individual.

Understand our evidence labels →

IDENTITY & STRUCTURE

What is Semaglutide?

Semaglutide (Ozempic / Wegovy / Rybelsus) is Semaglutide activates the GLP-1 receptor, a cell signal involved in insulin release and appetite. Randomized trials support benefits in defined populations; results and approved uses depend on the product, formulation and condition. Aliases include: Ozempic, Wegovy, Rybelsus, NN9535.

Chemical sequence and molecular parameters of Semaglutide
Primary sequence schematic · Inside Peptides Molecular Database
Chemical reference
Sequence (one-letter)
H-Aib-EGTFTSDVSSYLEGQAAK(diacid)EFIAWLVRGRG
Molecular formula
C187H291N45O59
Molecular weight
4113.6 g/mol
CAS Number
910463-68-2
UNII Code
53AXN4NNHX
PubChem CID
56843331

Identifiers checked against PubChem and FDA's Global Substance Registration System on 13 October 2026. FDA substance record ↗ · PubChem record ↗ See all names and codes in the peptide name index.

HUMAN RESEARCH

Clinical Trials & Human Cohorts

Human research can examine tolerability, symptoms or patient outcomes. The design and comparator determine what each result can establish.

Double-blind, placebo-controlled randomized trial; 68 weeks2021

Once-Weekly Semaglutide in Adults with Overweight or Obesity [1]

n = 1961Adults without diabetes; both groups received lifestyle support

What was reported

Mean weight change: −14.9% with studied injectable semaglutide versus −2.4% with placebo. Model-estimated difference: −12.4 percentage points (95% CI −13.4 to −11.5).

What limits the conclusion

Group averages are not individual guarantees. This formulation and population cannot establish effects for every semaglutide product or people with diabetes. Gastrointestinal-event discontinuation: 4.5% vs 0.8%.

Read primary source ↗ (external website)
Double-blind, placebo-controlled randomized trial2023

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes [2]

n = 17604Established cardiovascular disease plus overweight/obesity; no diabetes; mean follow-up 39.8 months

What was reported

Primary composite events: 569/8,803 (6.5%) vs 701/8,801 (8.0%). Hazard ratio 0.80 (95% CI 0.72–0.90); rounded absolute difference 1.5 percentage points.

What limits the conclusion

A 20% relative hazard reduction is not 20 fewer events per 100 people. Adverse-event permanent discontinuation: 16.6% vs 8.2%. This was not a trial of cardiovascular prevention in everyone without established disease.

Read primary source ↗ (external website)
Placebo-controlled randomized trial; median follow-up 3.4 years2024

Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes [3]

n = 3533Type 2 diabetes and chronic kidney disease; trial stopped early after prespecified interim analysis

What was reported

First primary-outcome events: 331 vs 410; hazard ratio 0.76 (95% CI 0.66–0.88). The composite included major kidney outcomes or death from kidney or cardiovascular causes.

What limits the conclusion

Composite components and absolute event rates matter; the result is not proof that every kidney disease or every participant benefits. Early stopping and the selected clinical population limit extrapolation.

Read primary source ↗ (external website)
MECHANISMS OF ACTION

How the compound may work

Mechanisms describe how Semaglutide may affect biological processes. Laboratory findings and patient outcomes answer different questions.

01
Established pharmacology

What receptor agonist means

An agonist activates a receptor. Semaglutide activates GLP-1 receptors and increases insulin release when glucose is high, reduces glucagon secretion and influences appetite. It also delays gastric emptying (food leaving the stomach). [4]

RESEARCH AREAS

Areas Being Studied

These research topics reflect active areas of scientific exploration, distinct from unverified commercial marketing claims.

Defined human populations

Weight and cardiovascular outcomes

STEP 1 and SELECT have different eligibility criteria and endpoints. Use the outcome-specific evidence rather than a single broad benefit claim. [2]

FLOW randomized trial

Kidney outcomes in type 2 diabetes

Clinical evidence concerns type 2 diabetes plus chronic kidney disease; it does not establish a universal kidney treatment. [3]

AT A GLANCE

Compare the study designs.

Overview of Key Semaglutide Studies: clinical and preclinical records
Study Design / sample Outcome type Key limitation
STEP 1: body weight · 2021 [1] Double-blind, placebo-controlled randomized trial; 68 weeks
n = 1961		 Clinical endpoint evaluation Group averages are not individual guarantees. This formulation and population cannot establish effects for every semaglutide product or people with diabetes. Gastrointestinal-event discontinuation: 4.5% vs 0.8%.
SELECT: cardiovascular events · 2023 [2] Double-blind, placebo-controlled randomized trial
n = 17604		 Clinical endpoint evaluation A 20% relative hazard reduction is not 20 fewer events per 100 people. Adverse-event permanent discontinuation: 16.6% vs 8.2%. This was not a trial of cardiovascular prevention in everyone without established disease.
FLOW: kidney/CV composite · 2024 [3] Placebo-controlled randomized trial; median follow-up 3.4 years
n = 3533		 Clinical endpoint evaluation Composite components and absolute event rates matter; the result is not proof that every kidney disease or every participant benefits. Early stopping and the selected clinical population limit extrapolation.
FDA & SAFETY

Regulatory Status & Clinical Safety

Regulatory Classification

United States, verified 10 October 2026: Ozempic injection covers type 2 diabetes and specified cardiovascular/kidney risk indications. Oral Rybelsus/Ozempic tablets have their own diabetes and cardiovascular indications. Wegovy injection and tablets cover defined weight and cardiovascular indications; pediatric and MASH indications differ by formulation. Injectable Wegovy’s adult noncirrhotic MASH indication (F2–F3 fibrosis) is accelerated approval with confirmatory requirements. Sharing an ingredient does not make labels interchangeable. [4][5][6]

Safety Realities & Impurities

Nausea, vomiting and diarrhea are common. Labels also describe pancreatitis, gallbladder disease, dehydration-related kidney injury and other risks. Boxed thyroid warnings arise from rodent findings; relevance to humans is unknown. Products are contraindicated with personal/family medullary thyroid carcinoma or MEN2 and specified hypersensitivity. This summary does not replace the current product label or clinical assessment. [4]

REGISTRY CHECK

Clinical Trials Registry Records

Official registry records from ClinicalTrials.gov. Study registration does not imply government endorsement or guaranteed efficacy.

COMPETITIVE SPORT

WADA & Anti-Doping Regulations

Not Prohibited

WADA Anti-Doping Status

Semaglutide is not prohibited under current World Anti-Doping Agency (WADA) regulations. However, athletes must ensure unregulated preparations or unverified vendor products do not violate Section S0 (Non-approved substances). Last verified: October 2026.

SELECTED MILESTONES

Research Timeline

  1. 2021

    STEP 1 published

    A 68-week randomized weight-management trial reports outcomes in adults without diabetes. [1]

  2. 2023

    SELECT published

    The study reports cardiovascular events in adults with pre-existing cardiovascular disease. [2]

  3. 2024

    FLOW published

    Kidney/CV composite outcomes reported for adults with type 2 diabetes and chronic kidney disease. [3]

OPEN QUESTIONS

What Researchers Still Don't Know

Individual response

Trial averages do not predict precisely how much a particular person will benefit or which adverse effects they will experience.

Different populations and products

Results must be matched to age, condition, formulation, comparator and follow-up. Benefits in one population do not establish another indication.

Longer horizons

Finite-duration randomized studies cannot resolve every rare or delayed effect. Postmarketing surveillance adds different evidence with its own limitations.

TRACEABLE SOURCES

References

Primary sources verified against PubMed / NLM and regulatory databases.

  1. Phase 3 RCT

    Once-weekly semaglutide in adults with overweight or obesity ↗ (external website)

    Wilding JPH et al. · N Engl J Med · 2021 DOI: 10.1056/NEJMoa2032183 ↗ (external website)
  2. Landmark RCT

    Semaglutide and cardiovascular outcomes in obesity without diabetes ↗ (external website)

    Lincoff AM et al. · N Engl J Med · 2023 DOI: 10.1056/NEJMoa2307563 ↗ (external website)
  3. Primary randomized trial

    Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes ↗ (external website)

    Perkovic V et al. · New England Journal of Medicine · 2024 DOI: 10.1056/NEJMoa2403347 ↗ (external website)
  4. Official prescribing information

    Wegovy injection and tablets, current U.S. label ↗ (external website)

    DailyMed / National Library of Medicine · 2026

    Revised June 2026; checked 10 October 2026.

  5. Official prescribing information

    Ozempic injection, current U.S. label ↗ (external website)

    DailyMed / National Library of Medicine · 2026
  6. Official prescribing information

    Rybelsus and Ozempic tablets, current U.S. label ↗ (external website)

    DailyMed / National Library of Medicine · 2026
  7. Official registry

    NCT03574597, SELECT ↗ (external website)

    ClinicalTrials.gov · 2026

    Official API record checked 10 October 2026.